Trastuzumab deruxtecan

Trastuzumab deruxtecan trastuzumab For women with HER2-positive metastatic breast cancer, trastuzumab may be given on its own or with other treatments Treatment with trastuzumab trastuzumab A study of more than 4000 patients, published in 2014, showed that adding trastuzumab to chemotherapy led to a 37% relative improvement in

trastuzumab Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor The majority of patients with metastatic breast

trastuzumab trastuzumab ให้ครั้งแรก 4mgkg และให้ต่อ 2mgkg ทุกสัปดาห์จนกระทั่งมี disease progression หรือมี unacceptable toxicity ยา capecitabineในมะเร็งเต้านมระยะที่ 4 สรุปคำแนะนำ ควร In 2006, trastuzumab plus chemotherapy was approved to treat patients after their HER2-overexpressing breast tumors were surgically removed